SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial

Key facts

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Intervention

Lenalidomide (Revlimid)(drug)

Enrollment

41 target

Eligibility

18-80 years · All sexes

Timeline

2025 – 2032

Study locations (1)

• 2nd Affiliated Hospital, School of Medicine, Hangzhou, Zhejiang, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Plasmacytoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07115667
  Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration
  Institute of Hematology & Blood Diseases Hospital, China
• RECRUITINGPHASE1, PHASE2NCT06429150
  Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
  Shenzhen Geno-Immune Medical Institute
• RECRUITINGPHASE2NCT05248633
  Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma
  Peking Union Medical College Hospital
• ACTIVE NOT RECRUITINGPHASE2NCT04174196
  A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma
  Memorial Sloan Kettering Cancer Center
• ACTIVE NOT RECRUITINGPHASE2NCT04166565
  Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease
  Stichting European Myeloma Network
• ACTIVE NOT RECRUITINGPHASE3NCT02544308
  Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma
  University College, London

See all trials for Plasmacytoma →